Twist and Ildong to develop antibodies for immuno-oncology applications
Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.

Under the deal, Twist will receive upfront, milestone and royalty payments as well as annual maintenance fees.
The boards of directors of Zura Bio and JATT granted approval for the business combination.
W0180 is presently being analysed in a Phase I clinical trial for various solid tumours.
Sanofi and Regeneron’s Dupixent, indicated to treat atopic dermatitis, is anticipated to reach sales of $5.3bn in the US by…
ByThe global osteoarthritis space has a high level of unmet medical need, primarily due to the lack of disease-modifying drugs.
ByRegeneron will make an upfront payment of $900m to Sanofi as well as a 11% royalty on global net sales…
Conventional analgesics prescribed for osteoarthritis offer inadequate pain relief and are associated with several adverse events.
ByLeveraging the TriNKET platform of Dragonfly, the alliance will develop drug candidates for immune-mediated diseases.
Thank you for subscribing to Pharmaceutical Technology